Show Notes
Imagine knowing your risk for disease long before symptoms appear. With early detection and targeted interventions, this knowledge could transform how complex healthcare challenges are addressed. Researchers are now leveraging genetic data to enhance disease risk prediction through an innovative tool known as a polygenic risk score. The episode features Victor Ortega, M.D., Ph.D., associate director of the Mayo Clinic Center for Individualized Medicine and Louise Wain, Ph.D., professor of respiratory research, University of Leicester. Get the latest health information from Mayo Clinic's experts, subscribe to Mayo Clinic’s newsletter for free today: https://mayocl.in/3EcNPNc
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What happens when multiple sclerosis symptoms mask a different condition?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.